NCT01700751View on ClinicalTrials.gov

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 25, 2013

Primary Completion Date

November 11, 2015

Study Completion Date

November 21, 2016

Conditions
Leukemia, Acute MyeloidLeukemia, Lymphoblastic,AcuteMyelodysplastic Syndromes
Interventions
DRUG

brentuximab vedotin

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01700751 - Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter